Correction to: Updates on cardiovascular outcome trials in diabetes
| العنوان: | Correction to: Updates on cardiovascular outcome trials in diabetes |
|---|---|
| المؤلفون: | Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello, on behalf of the D&CVD EASD Study Group |
| المصدر: | Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-4 (2017) Cardiovascular Diabetology |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, MEDLINE, Alternative medicine, 030209 endocrinology & metabolism, Review, 030204 cardiovascular system & hematology, Outcome (game theory), Glucagon-Like Peptide-1 Receptor, CVOT, 03 medical and health sciences, 0302 clinical medicine, Sodium-Glucose Transporter 2, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Intensive care medicine, Sodium-Glucose Transporter 2 Inhibitors, ACE, Angiology, Clinical Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, DEVOTE, CANVAS program, business.industry, Published Erratum, Diabetes, EXSCEL, Correction, Heart, Cardiovascular risk, medicine.disease, Diabetes Mellitus, Type 2, Cardiovascular Diseases, lcsh:RC666-701, Cardiology, Cardiology and Cardiovascular Medicine, business |
| الوصف: | In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years. |
| تدمد: | 1475-2840 |
| DOI: | 10.1186/s12933-017-0633-4 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1cbaf90f32bed516bb20062b4052baa https://doi.org/10.1186/s12933-017-0633-4 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b1cbaf90f32bed516bb20062b4052baa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14752840 |
|---|---|
| DOI: | 10.1186/s12933-017-0633-4 |